FX.co ★ Pharming Group Offers To Acquire Abliva For SEK 0.45/shr In Cash

Pharming Group N.V. (PHAR) has announced a public cash offer to purchase all issued and outstanding shares of Abliva AB at a rate of SEK 0.45 per share. This acquisition is valued at approximately USD 66.1 million. Abliva's Board of Directors has advised shareholders to accept this offer. The acceptance period is anticipated to begin on or around January 16, 2025, and conclude on or around February 7, 2025. Abliva's leading product, KL1333, is undergoing a pivotal clinical trial and has shown positive interim results for treating mitochondrial DNA-driven primary mitochondrial diseases.